Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	11.30B
Revenue (ttm)	1.44B
Net Income (ttm)	435.66M
Shares Out	70.00M
EPS (ttm)	6.22
PE Ratio	25.93
Forward PE	24.11
Dividend	3.06 (1.90%)
Ex-Dividend Date	Jul 29, 2025

Volume	19,369
Average Volume	48,395
Open	162.50
Previous Close	161.40
Day's Range	158.90 - 162.50
52-Week Range	134.00 - 202.40
Beta	0.90
RSI	35.50
Earnings Date	Aug 5, 2025

About Avangrid

Jamjoom Pharmaceuticals Factory Company manufactures and markets pharmaceutical products in the Kingdom of Saudi Arabia and internationally. The company offers products human medicines, nutraceuticals, antibiotics, general analgesics, medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, ulcer, and acidity, as well as various skin infections, cancer diseases, eye drops and ointments, and cosmeceuticals. Jamjoom Pharmaceuticals Factory Company was founded in 1994 and is based in Jeddah, the Kingdo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Country: Saudi Arabia
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.